IRIS Accounts Production v23.3.1.45 09349218 director 1.1.23 31.12.23 31.12.23 false true false false false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh093492182022-12-31093492182023-12-31093492182023-01-012023-12-31093492182021-12-31093492182022-01-012022-12-31093492182022-12-3109349218ns10:Originalns15:EnglandWales2023-01-012023-12-3109349218ns14:PoundSterlingns10:Original2023-01-012023-12-3109349218ns10:Originalns10:Director12023-01-012023-12-3109349218ns10:Original2023-01-012023-12-3109349218ns10:Original2023-12-3109349218ns10:Originalns10:PrivateLimitedCompanyLtd2023-01-012023-12-3109349218ns10:Originalns10:Micro-entities2023-01-012023-12-3109349218ns10:Originalns10:AuditExempt-NoAccountantsReport2023-01-012023-12-3109349218ns10:Originalns10:FullAccounts2023-01-012023-12-3109349218ns10:Originalns10:RegisteredOffice2023-01-012023-12-3109349218ns10:Original2022-12-3109349218ns10:Originalns5:CurrentFinancialInstruments2023-12-3109349218ns10:Originalns5:CurrentFinancialInstruments2022-12-3109349218ns10:Original2022-01-012022-12-3109349218ns10:Original1ns10:Director12022-12-3109349218ns10:Original1ns10:Director12021-12-3109349218ns10:Original1ns10:Director12023-01-012023-12-3109349218ns10:Original1ns10:Director12022-01-012022-12-3109349218ns10:Original1ns10:Director12023-12-3109349218ns10:Original1ns10:Director12022-12-31
REGISTERED NUMBER: 09349218 (England and Wales)















Unaudited Financial Statements for the Year Ended 31 December 2023

for

KJL PHARMA VALIDATION CONSULTANT LIMITED

KJL PHARMA VALIDATION CONSULTANT LIMITED (by shares)
(Registered number: 09349218)






Contents of the Financial Statements
for the Year Ended 31 December 2023




Page

Company Information 1

Balance Sheet 2


KJL PHARMA VALIDATION CONSULTANT LIMITED (by shares)

Company Information
for the Year Ended 31 December 2023







DIRECTOR: K Loring





REGISTERED OFFICE: 10 Spruce Close
West Mersea
Colchester
Essex
CO5 8PU





REGISTERED NUMBER: 09349218 (England and Wales)






KJL PHARMA VALIDATION CONSULTANT LIMITED (by shares)
(Registered number: 09349218)

Balance Sheet
31 December 2023

31.12.23 31.12.22
£    £   
CURRENT ASSETS 79,502 111,260

CREDITORS
Amounts falling due within one year - (20,051 )
NET CURRENT ASSETS 79,502 91,209
TOTAL ASSETS LESS CURRENT
LIABILITIES

79,502

91,209

CAPITAL AND RESERVES 79,502 91,209

NOTES TO THE FINANCIAL STATEMENTS

1. AVERAGE NUMBER OF EMPLOYEES

The average number of employees during the year was 1 (2022 - 2 ) .

2. DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the years ended 31 December 2023 and 31 December 2022:

31.12.23 31.12.22
£    £   
K Loring
Balance outstanding at start of year 1 -
Amounts advanced - 1
Amounts repaid (1 ) -
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year - 1



The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

KJL PHARMA VALIDATION CONSULTANT LIMITED (by shares)
(Registered number: 09349218)

Balance Sheet - continued
31 December 2023


The financial statements have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the director and authorised for issue on 8 February 2024 and were signed by:





K Loring - Director